<?xml version="1.0" encoding="UTF-8"?>
<p>Participants in the ‘SPOT’ study included PD patients and genetically unrelated controls (mostly spouses) from the Center for Parkinson’s Disease at Columbia University Medical Center in New York, NY, recruited between 2010 and 2014.
 <sup>
  <xref ref-type="bibr" rid="bib14">14</xref>
 </sup> The cohort has been previously described.
 <sup>
  <xref ref-type="bibr" rid="bib12">12</xref>
 </sup> In brief, a blood sample and the data on demographics, medical history, medication, PD family history,
 <sup>
  <xref ref-type="bibr" rid="bib15">15</xref>
 </sup> the Unified Parkinson’s Disease Rating Scale (UPDRS) in the ‘on’ state and the Montreal Cognitive Assessment (MoCA)
 <sup>
  <xref ref-type="bibr" rid="bib16">16</xref>
 </sup> were collected from consecutive PD cases, as defined by the United Kingdom PD brain bank criteria (except that we did not exclude cases with a family history of PD).
 <sup>
  <xref ref-type="bibr" rid="bib17">17</xref>
 </sup> A blood sample was collected from genetically unrelated control individuals, mostly spouses. All study procedures were approved by the Columbia University IRB, and all participants signed informed consent.
</p>
